Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
91 Leser
Artikel bewerten:
(0)

Lorillard Tobacco's Principal Scientist to Represent Tobacco Industry on FDA's Scientific Advisory Committee

GREENSBORO, N.C., March 24 /PRNewswire-FirstCall/ -- Lorillard Tobacco Company today issued the following statement after notification that Dr. J. Daniel Heck, the company's principal scientist, will serve as a non-voting representative of the tobacco manufacturing industry on the Tobacco Products Scientific Advisory Committee of the Food and Drug Administration.

"With the full membership of the Tobacco Products Scientific Advisory Committee now in place, Lorillard looks forward to working with the Committee and contributing to its scientific review of menthol and other topics," the company said. "Lorillard remains confident that a serious examination of menthol science will show that the best available science does not support an assertion that menthol impacts public health.

"Dr. Heck has more than 30 years of professional experience in research and a strong record of peer-reviewed articles and studies," the company added. "We are honored that he will serve as the representative of the tobacco manufacturing industry on the Committee, and we are confident his expertise will contribute to a fair hearing that is grounded in good science that advances public policy."

Dr. Heck's most recent manuscript, a comprehensive review of the use of menthol as a cigarette flavoring, was published in the January 2010 issue of Food and Chemical Toxicology.

Dr. Heck earned his doctorate in pharmacology and toxicology from the Graduate School of Biomedical Sciences at the University of Texas Health Sciences Center in Houston. He has served as Principal Scientist at Lorillard since 2003.

Dr. Heck is a Diplomate to the American Board of Toxicology and a member of the Society of Toxicology. He has served and continues to serve on numerous professional committees, including the Safety Evaluation Coordinating Committee of the Flavor and Extract Manufacturers Association (FEMA) of the United States and the Cigarettes Ingredients Scientific Panel. Dr. Heck also peer reviews manuscripts for many prominent publications, including Toxicological Sciences and Food and Chemical Toxicology, and also serves on the editorial board of Inhalation Toxicology and Beiträge zur Tabakforschung International.

About Lorillard, Inc.

Lorillard, Inc. is the third largest manufacturer of cigarettes in the United States. Founded in 1760, Lorillard is the oldest continuously operating tobacco company in the U.S. Newport®, Lorillard's flagship menthol-flavored premium cigarette brand, is the top selling menthol and second largest selling cigarette in the U.S. In addition to Newport, the Lorillard product line has five additional brand families marketed under the Kent®, True®, Maverick®, Old Gold® and Max® brand names. These six brands include 41 different product offerings which vary in price, taste, flavor, length and packaging. Lorillard maintains its headquarters and manufactures all of its products in Greensboro, North Carolina. For more information, visit the Company's web site at http://www.lorillard.com/.

Forward-Looking Statements

Certain statements made in this press release are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, or the Reform Act. Forward-looking statements include, without limitation, any statement that may project, indicate or imply future results, events, performance or achievements, and may contain the words "expect", "intend", "plan", "anticipate", "estimate", "believe", "may", "will be", "will continue", "will likely result", and similar expressions. In addition, any statement that may be provided by management concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible actions by Lorillard, Inc. are also forward-looking statements as defined by the Reform Act.

Forward-looking statements are based on current expectations and projections about future events and are inherently subject to a variety of risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those anticipated or projected. Information describing factors that could cause actual results to differ materially from those in forward-looking statements is available in Lorillard, Inc.'s filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings are available from the SEC over the Internet or in hard copy, and are available on our website at http://www.lorillard.com/. Forward-looking statements speak only as of the time they are made, and we expressly disclaim any obligation or undertaking to update these statements to reflect any change in expectations or beliefs or any change in events, conditions or circumstances on which any forward-looking statement is based.

Contact: Gregg Perry +1-401-886-7200

Lorillard, Inc.

CONTACT: Gregg Perry +1-401-886-7200, for Lorillard, Inc.

Web Site: http://www.lorillard.com/

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.